Annelise Vuidepot
Chief Science & Technology Officer Immunocore
Seminars
Monday 8th June 2026
Exploring a Novel Mechanism of Action with the Development of TCR– PD-1 Agonist Bispecifics for the Treatment of Autoimmune Diseases
3:00 pm
- Aiming to deliver tissue-specific TCR-based therapeutics
- Adapting the ImmTAC platform with a novel effector function to address autoimmune diseases
- Exploring the development of a beta-cell–targeted immune-suppressive PD-1 agonist bispecific to treat type I diabetes
